NCT03375086 - A Study of APX3330 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

August 18, 2018

Study Completion Date

January 9, 2019

Conditions

Cancer

Interventions

DRUG

APX3330

APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.

Trial Locations (3)

46202

Indiana University Simon Cancer Center, Indianapolis

49546

START Midwest, Grand Rapids

78229

START San Antonio, San Antonio